Idarucizumab functions by binding to dabigatran molecules, thereby preventing them from interacting with thrombin. This binding is specific and rapid, occurring within minutes after administration. By neutralizing dabigatranâs anticoagulant effect, idarucizumab allows the body's natural coagulation processes to resume, thereby reducing bleeding risk and facilitating surgical interventions when needed.
